On­cono­va re­ports PhI­II flop, putting high-risk MDS pro­gram on the chop­ping block

Be­lea­guered biotech On­cono­va ran in­to an­oth­er set­back Mon­day morn­ing as a Phase III for its lead pro­gram flopped once again.

The tri­al re­sults for rigosert­ib …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER